throbber
Case 2:22-cv-00903 Document 1 Filed 02/18/22 Page 1 of 28 PageID: 1
`
`THE ROSEN LAW FIRM, P.A.
`Laurence Rosen, Esq.
`One Gateway Center, Suite 2600
`Newark, NJ 07102
`Tel: (973) 313-1887
`Fax: (973) 833-0399
`Email: lrosen@rosenlegal.com
`
`Counsel for Plaintiff
`
`UNITED STATES DISTRICT COURT
`DISTRICT OF NEW JERSEY
`
`CHRISTINA PHAM, Individually and
`on behalf of all others similarly situated,
`
`Case No:
`
`CLASS ACTION COMPLAINT
`FOR VIOLATIONS OF THE
`FEDERAL SECURITIES LAWS
`
`JURY TRIAL DEMANDED
`
`Plaintiff,
`
`v.
`
`REATA PHARMACEUTICALS, INC.,
`J. WARREN HUFF, and MANMEET S.
`SONI,
`
`Defendants.
`
`Plaintiff Christina Pham (“Plaintiff”), individually and on behalf of all other
`
`persons similarly situated, by Plaintiff’s undersigned attorneys, for Plaintiff’s
`
`complaint against Defendants (defined below), alleges the following based upon
`
`personal knowledge as to Plaintiff and Plaintiff’s own acts, and information and
`
`belief as to all other matters, based upon, inter alia, the investigation conducted
`
`by and through her attorneys, which included, among other things, a review of
`
`the Defendants’ public documents, conference calls and announcements
`
`made by
`
`1
`
`

`

`Case 2:22-cv-00903 Document 1 Filed 02/18/22 Page 2 of 28 PageID: 2
`
`
`
`
`
`Defendants, public filings, wire and press releases published by and regarding
`
`Reata Pharmaceuticals, Inc. (“Reata” or the “Company”), and information readily
`
`obtainable on the Internet. Plaintiff believes that substantial evidentiary support
`
`will exist for the allegations set forth herein after a reasonable opportunity for
`
`discovery.
`
`NATURE OF THE ACTION
`
`1.
`
`This is a class action on behalf of persons or entities who purchased
`
`or otherwise acquired publicly traded Reata securities between November 9, 2020
`
`and December 8, 2021, inclusive (the “Class Period”). Plaintiff seeks to recover
`
`compensable damages caused by Defendants’ violations of the federal securities
`
`laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
`
`JURISDICTION AND VENUE
`
`2.
`
`The claims asserted herein arise under and pursuant to Sections 10(b)
`
`and 20(a) of the Exchange Act (15 U.S.C. §§ 78j(b) and 78t(a)) and Rule 10b-5
`
`promulgated thereunder by the SEC (17 C.F.R. § 240.10b-5).
`
`3.
`
`This Court has jurisdiction over the subject matter of this action
`
`pursuant to 28 U.S.C. § 1331, and Section 27 of the Exchange Act (15 U.S.C.
`
`§78aa).
`
`4.
`
`Venue is proper in this judicial district pursuant to 28 U.S.C. §
`
`1391(b) and Section 27 of the Exchange Act (15 U.S.C. § 78aa(c)) as the alleged
`
`2
`
`

`

`Case 2:22-cv-00903 Document 1 Filed 02/18/22 Page 3 of 28 PageID: 3
`
`
`
`
`
`misstatements entered and the subsequent damages took place in this judicial
`
`district.
`
`5.
`
`In connection with the acts, conduct and other wrongs alleged in this
`
`complaint, Defendants (defined below), directly or indirectly, used the means and
`
`instrumentalities of interstate commerce, including but not limited to, the United
`
`States mails, interstate telephone communications and the facilities of the national
`
`securities exchange.
`
`PARTIES
`
`6.
`
`Plaintiff, as set forth in the accompanying certification, incorporated
`
`by reference herein, purchased Reata securities during the Class Period and was
`
`economically damaged thereby.
`
`7.
`
`Defendant Reata is a clinical-stage biopharmaceutical company that
`
`focuses on small-molecule therapeutics. One of its two lead product candidates is
`
`bardoxolone methyl (“bardoxolone”), which is being developed for multiple
`
`indications, including chronic kidney disease (“CKD”) caused by Alport
`
`syndrome (“AS”). Reata is incorporated under the laws of Delaware with its
`
`principal executive offices located in Plano, Texas. Reata’s Class A common
`
`stock trades on the NASDAQ exchange (“NASDAQ”) under the symbol “RETA.”
`
`8.
`
`Defendant J. Warren Huff (“Huff”) was the Company’s Chief
`
`Executive Officer at all relevant times.
`
`3
`
`

`

`Case 2:22-cv-00903 Document 1 Filed 02/18/22 Page 4 of 28 PageID: 4
`
`
`
`
`
`9.
`
`Defendant Manmeet S. Soni (“Soni”) was the Company’s Chief
`
`Financial Officer at all relevant times.
`
`10. Defendants Huff and Soni are collectively referred to herein as the
`
`“Individual Defendants.”
`
`11. Each of the Individual Defendants:
`
`(a)
`
`directly participated in the management of the Company;
`
`(b) was directly involved in the day-to-day operations of the
`
`Company at the highest levels;
`
`(c) was privy to confidential proprietary information concerning
`
`the Company and its business and operations;
`
`(d) was directly or indirectly involved in drafting, producing,
`
`reviewing and/or disseminating the false and misleading
`
`statements and information alleged herein;
`
`(e) was directly or indirectly involved in the oversight or
`
`implementation of the Company’s internal controls;
`
`(f) was aware of or recklessly disregarded the fact that the false
`
`and misleading statements were being issued concerning the
`
`Company; and/or
`
`(g)
`
`approved or ratified these statements in violation of the federal
`
`securities laws.
`
`4
`
`

`

`Case 2:22-cv-00903 Document 1 Filed 02/18/22 Page 5 of 28 PageID: 5
`
`
`
`
`
`12. Reata is liable for the acts of the Individual Defendants and its
`
`employees under the doctrine of respondeat superior and common law principles
`
`of agency because all of the wrongful acts complained of herein were carried out
`
`within the scope of their employment.
`
`13. The scienter of the Individual Defendants and other employees and
`
`agents of the Company is similarly imputed to Reata under respondeat superior
`
`and agency principles.
`
`14. Defendant Reata and the Individual Defendants are collectively
`
`referred to herein as “Defendants.”
`
`SUBSTANTIVE ALLEGATIONS
`
`Materially False and Misleading
`
`Statements Issued During the Class Period
`
`15. The Class Period begins on November 9, 2020. On that day, Reata
`
`announced the results from Year 2 of the Phase 3 CARDINAL study in a press
`
`release that stated, in relevant part:
`
`the
`(“Reata” or
`(Nasdaq:RETA)
`Inc.
`Reata Pharmaceuticals,
`“Company,” or “we”), a clinical-stage biopharmaceutical company,
`today announced that the Phase 3 CARDINAL study of bardoxolone
`methyl (“bardoxolone”) in patients with chronic kidney disease
`(“CKD”) caused by Alport syndrome met its primary and key
`secondary endpoints at the end of Year 2. At Week 100, in the intent-
`to-treat (“ITT”) population, which included estimated glomerular
`filtration rate (“eGFR”) values for patients who either remained on or
`discontinued study drug, patients treated with bardoxolone had a
`statistically significant improvement compared to placebo in mean
`change from baseline in eGFR of 7.7 mL/min/1.73 m2 (p=0.0005). In
`
`5
`
`

`

`Case 2:22-cv-00903 Document 1 Filed 02/18/22 Page 6 of 28 PageID: 6
`
`
`
`
`
`the modified ITT (“mITT”) analysis, which assessed the effect of
`receiving treatment by excluding values after patients discontinued
`treatment, patients treated with bardoxolone had a statistically
`significant improvement compared to placebo in mean change from
`baseline in eGFR at Week 100 of 11.3 mL/min/1.73 m2 (p<0.0001).
`At Week 104 (four weeks after last dose in second year of treatment),
`patients in the ITT population treated with bardoxolone had a
`statistically significant improvement compared to placebo in mean
`change from baseline in eGFR of 4.3 mL/min/1.73 m2 (p=0.023).
`Bardoxolone treatment was generally reported to be well-tolerated. In
`the long-term extension study (“EAGLE”), for the 14 patients who
`completed three years of treatment, bardoxolone treatment resulted in
`a mean increase from baseline in eGFR of 11.0 mL/min/1.73 m2.
`Based on these positive results and following a recently completed
`pre-NDA meeting with the U.S. Food and Drug Administration
`(“FDA”), we plan to proceed with the submission of an NDA for full
`marketing approval in the United States in the first quarter of 2021.
`We also plan to pursue marketing approval outside of the United
`States and work has commenced on preparations to file for marketing
`approval in Europe.
`
`
`* * *
`
`“Chronic kidney disease caused by Alport syndrome is a serious,
`progressive disease with an urgent need for new therapeutic options.
`The two-year CARDINAL study, now complete, represents the first
`time that an investigational medicine has shown a significant
`clinical benefit in this disease, and it marks an important step toward
`making a treatment available for patients with Alport syndrome. We
`look forward
`to submitting our New Drug Application for
`bardoxolone in the first quarter of 2021. On behalf of everyone at
`Reata, I would like to express my sincere appreciation to all of the
`patients, families, and
`investigators who participated
`in
`the
`CARDINAL study,” said Warren Huff, Reata’s President and Chief
`Executive Officer.
`
`
`* * *
`
`
`In rare forms of CKD, the FDA has accepted the off-treatment
`endpoint as the basis for approval. Withdrawal of drug after long-
`
`6
`
`

`

`Case 2:22-cv-00903 Document 1 Filed 02/18/22 Page 7 of 28 PageID: 7
`
`
`
`
`
`term treatment provides evidence whether a drug either protected or
`harmed the kidney during treatment. If off-treatment changes in eGFR
`are higher than placebo, this is evidence that the drug protected the
`kidney during treatment, and, if off-treatment changes in eGFR are
`lower than placebo, this is evidence that the drug harmed the kidney
`during treatment. An off-treatment eGFR benefit relative to placebo
`provides evidence that drug treatment may delay kidney failure.
`
`(Emphasis added.)
`
`16. Also on November 9, 2020, the Company filed its quarterly report on
`
`Form 10-Q for the period ended September 30, 2020, stating, in relevant part:
`
`Bardoxolone for CKD Caused by Alport Syndrome
`
`On November 9, 2020, we announced that the Phase 3 CARDINAL
`study of bardoxolone in patients with CKD caused by Alport
`syndrome met its primary and key secondary endpoints at the end of
`Year 2. At Week 100, in the intent-to-treat (ITT) population, which
`included eGFR values for patients who either remained on or have
`discontinued study drug, patients treated with bardoxolone had a
`statistically significant improvement compared to placebo in mean
`change from baseline in estimated glomerular filtration rate (eGFR) of
`7.7 mL/min/1.73 m2 (p=0.0005). In the modified ITT (mITT)
`analysis, which assessed the effect of receiving treatment by
`excluding values after patients discontinued treatment, patients treated
`with bardoxolone had a statistically significant
`improvement
`compared to placebo in mean change from baseline in eGFR at Week
`100 of 11.3 mL/min/1.73 m2 (p<0.0001). At Week 104 (four weeks
`after last dose in second year of treatment), patients in the ITT
`population treated with bardoxolone had a statistically significant
`improvement compared to placebo in mean change from baseline in
`eGFR of 4.3 mL/min/1.73 m2 (p=0.023). Bardoxolone treatment was
`generally reported to be well-tolerated. Based on these positive
`results and following a recently completed pre-NDA meeting with
`the U.S. Food and Drug Administration (FDA), we plan to proceed
`with the submission of an NDA for full marketing approval in the
`United States in the first quarter of 2021. We also plan to pursue
`
`7
`
`

`

`Case 2:22-cv-00903 Document 1 Filed 02/18/22 Page 8 of 28 PageID: 8
`
`
`
`
`
`marketing approval outside of the United States and work has
`commenced on preparations to file for marketing approval in Europe.
`
`(Emphasis added.)
`
`17. On March 1, 2021, Reata announced that it had submitted its NDA
`
`for bardoxolone as a treatment of CKD caused by AS. The Company’s press
`
`release stated, in relevant part:
`
`the
`(“Reata,”
`(Nasdaq: RETA)
`Inc.
`Reata Pharmaceuticals,
`“Company,” or “we”), a clinical-stage biopharmaceutical company,
`today announced that it has submitted a New Drug Application
`(“NDA”) for bardoxolone methyl (“bardoxolone”) for the treatment of
`chronic kidney disease (“CKD”) caused by Alport syndrome to the
`U.S. Food and Drug Administration (“FDA”).
`
`This NDA submission is based on the efficacy and safety data from
`the CARDINAL Phase 3 clinical trial. The submission includes a
`request for Priority Review, which, if granted, would shorten the
`FDA’s review of the NDA to eight months from the time of
`submission, versus a standard review timeline of 12 months. If
`approved, bardoxolone would become the first therapy specifically
`indicated for the treatment of CKD caused by Alport syndrome.
`
`“This NDA submission marks an important step toward making a
`treatment available for patients with Alport syndrome, a serious,
`progressive disease with an urgent need for new therapeutic options,”
`said Warren Huff, Reata’s President and Chief Executive Officer. “I
`want to thank all those who made this moment possible, especially
`Alport syndrome patients and their families. We look forward to next
`steps on the path to making bardoxolone available as a first-in-class
`therapy for Alport syndrome, pending NDA acceptance, review, and
`drug approval.”
`
`(Emphasis added.)
`
`
`8
`
`

`

`Case 2:22-cv-00903 Document 1 Filed 02/18/22 Page 9 of 28 PageID: 9
`
`
`
`
`
`18. Also on March 1, 2021, Reata filed its annual report on Form 10-K
`
`for the period ended December 31, 2020. Regarding risks impacting regulatory
`
`approval of any of its product candidates, Reata stated, in relevant part:
`
`The clinical and commercial success of bardoxolone and
`omaveloxolone will depend on a number of factors, many of which
`are beyond our control.
`
`success of bardoxolone and
`The clinical and commercial
`omaveloxolone will depend on a number of factors, including the
`following, many of which are beyond our control:
`
`
`• the timely initiation, continuation, and completion of our Phase
`2 and Phase 3 clinical
`trials
`for bardoxolone and
`omaveloxolone, which will depend
`substantially upon
`requirements for such trials imposed by the FDA and other
`regulatory agencies and bodies;
`• our ability to demonstrate the safety and efficacy of our product
`candidates to the satisfaction of the relevant regulatory
`authorities;
`• whether the FDA or other regulatory authorities will accept
`NDAs for approval of our product candidates;
`• whether we are required by the FDA or other regulatory
`authorities to conduct additional clinical trials, and the scope
`and nature of such clinical trials, prior to approval to market our
`products;
`• the timely receipt of necessary marketing approvals from the
`FDA and foreign regulatory authorities, including pricing and
`reimbursement determinations;
`• the ability to successfully commercialize our product candidates
`for marketing and sale, if approved by the FDA or foreign
`regulatory authorities, whether alone or in collaboration with
`others;
`• our ability and the ability of third-party manufacturers to
`manufacture the quantities of our product candidates with
`quality attributes necessary to meet regulatory requirements and
`
`9
`
`

`

`Case 2:22-cv-00903 Document 1 Filed 02/18/22 Page 10 of 28 PageID: 10
`
`
`
`
`
`at a scale and yield sufficient to meet anticipated demand at a
`cost that allows us to achieve profitability;
`• our success in educating health care providers and patients
`about the benefits, risks, administration, and use of our product
`candidates, if approved;
`• acceptance of our product candidates, if approved, as safe and
`effective by patients and the healthcare community;
`• the achievement and maintenance of compliance with all
`regulatory requirements applicable to our product candidates,
`our third-party manufacturers, and our internal operations;
`• the maintenance of an acceptable safety profile of our products,
`if any, following any approval;
`• the availability, perceived advantages, relative cost, relative
`safety, and relative efficacy of alternative and competitive
`treatments;
`• our ability to provide approved product with a convenient and
`patient-friendly capsule configuration;
`• our ability to successfully enforce our intellectual property
`rights for our product candidates and against the products of
`potential competitors; and
`• our ability to avoid or succeed in third-party patent interference
`or patent infringement claims.
`
`
`We cannot assure you that we will ever be able to achieve profitability
`through the sale of, or royalties from, our product candidates. If we or our
`collaborators are not successful
`in obtaining approval for and
`commercializing our product candidates, or are delayed in completing
`those efforts, our business and operations would be adversely affected.
`
`(Emphasis added.)
`
`
`19. On April 26, 2021, Reata announced that the FDA had accepted the
`
`NDA submission and set an action date for February 25, 2022. The Company’s
`
`press release stated, in relevant part:
`
`the
`(“Reata,”
`(Nasdaq: RETA)
`Inc.
`Reata Pharmaceuticals,
`“Company,” or “we”), a clinical-stage biopharmaceutical company,
`
`10
`
`

`

`Case 2:22-cv-00903 Document 1 Filed 02/18/22 Page 11 of 28 PageID: 11
`
`
`
`
`
`today announced that the U.S. Food and Drug Administration
`(“FDA”) accepted for filing the New Drug Application (“NDA”) for
`bardoxolone methyl (“bardoxolone”) for the treatment of patients with
`chronic kidney disease (“CKD”) caused by Alport syndrome.
`
`This NDA submission is based on the efficacy and safety data from
`the CARDINAL Phase 3 clinical trial. The FDA will review the
`application under a Standard Review timeline. The Prescription Drug
`User Fee Act (“PDUFA”) date, the FDA action date for the
`application, is scheduled for February 25, 2022. The FDA also
`advised the Company that it is currently planning to hold an Advisory
`Committee meeting to discuss the application.
`
`“We are pleased with the FDA’s decision to accept for filing our NDA
`for bardoxolone and look forward to continuing to work with the
`Division during the review process,” said Warren Huff, Reata’s
`President and Chief Executive Officer. “Alport syndrome is one of the
`most rapidly progressive forms of CKD and a truly devastating
`disease to those patients and the families who are affected by it. If
`approved, bardoxolone may be the first therapy to slow the
`progression of kidney disease in patients with this serious and
`debilitating disease.”
`
`(Emphasis added.)
`
`20. On May 6, 2021, Reata announced its first quarter 2021 financial
`
`results and provided an update on its clinical development programs. The press
`
`release stated, among other things:
`
`Recent Company Highlights
`
`Bardoxolone Methyl (“Bardoxolone”)
`Syndrome
`
`In April 2021, we announced that the U.S. Food and Drug
`Administration (“FDA”) accepted for filing Reata’s New Drug
`Application (“NDA”) for bardoxolone for the treatment of patients
`with chronic kidney disease (“CKD”) caused by Alport syndrome.
`
`in Patients with Alport
`
`11
`
`

`

`Case 2:22-cv-00903 Document 1 Filed 02/18/22 Page 12 of 28 PageID: 12
`
`
`
`
`
`The FDA will review the application under a Standard Review
`timeline. The Prescription Drug User Fee Act (“PDUFA”) date, the
`FDA action date for the application, is scheduled for February 25,
`2022. The FDA also advised us that it is currently planning to hold
`an Advisory Committee meeting to discuss the application. If
`approved, bardoxolone may become the first therapy specifically
`indicated for the treatment of CKD caused by Alport syndrome.
`
`“We made significant progress during the first quarter of 2021 with
`the submission of our NDA for bardoxolone for the treatment of CKD
`caused by Alport syndrome coming less than four months after
`reporting positive results from Year 2 of our Phase 3 CARDINAL
`trial,” said Warren Huff, Reata’s President and Chief Executive
`Officer. “Alport syndrome is a devastating disease that affects 30,000
`to 60,000 patients in the United States. We are pleased with the
`FDA’s recent decision to accept our application for filing and look
`forward to continuing to work with the FDA during its review of our
`application.”
`
`(Emphasis added.)
`
`21. On May 6, 2021, Reata filed its quarterly report on Form 10-Q for the
`
`period ended March 31, 2021, stating, in relevant part:
`
`Bardoxolone in Patients with CKD Caused by Alport Syndrome
`
`On April 26, 2021, we announced that the U.S. Food and Drug
`Administration (FDA) accepted for filing the New Drug Application
`(NDA) for bardoxolone for the treatment of patients with CKD caused
`by Alport syndrome. The FDA will review the application under a
`Standard Review timeline. The Prescription Drug User Fee Act
`(PDUFA) date, the FDA action date for the application, is scheduled
`for February 25, 2022. The FDA also advised us that it is currently
`planning to hold an Advisory Committee meeting to discuss the
`application.
`
`Our NDA submission was based on the results of Year 2 of the Phase
`3 CARDINAL study of bardoxolone in patients with CKD caused by
`Alport syndrome announced in November 2020. The study met its
`
`12
`
`

`

`Case 2:22-cv-00903 Document 1 Filed 02/18/22 Page 13 of 28 PageID: 13
`
`
`
`
`
`primary and key secondary endpoints following two years of
`treatment (referred to as Year 2). Moreover, we also announced that
`patients who completed one year in the EAGLE long-term extension
`study and were treated with bardoxolone for a total of three years
`(n=14) showed a sustained and significant increase from baseline in
`estimated glomerular filtration rate (eGFR). Together, these data
`suggest that bardoxolone treatment has beneficial long-term effects
`on kidney function in patients with Alport syndrome.
`
`(Emphasis added.)
`
`22. On August 9, 2021, Reata announced its second quarter 2021
`
`financial results and provided an update on its clinical development programs. The
`
`press release stated that, during a mid-cycle communication meeting about the
`
`NDA, the FDA had “identified four significant clinical and statistical review
`
`issues” for Reata to address. Specifically, the Company stated:
`
`in Patients with Alport
`
`Bardoxolone Methyl (“Bardoxolone”)
`Syndrome
`
`The NDA for bardoxolone for the treatment of patients with chronic
`kidney disease (“CKD”) caused by Alport syndrome is currently
`under review by the FDA. The FDA completed a bio-research
`monitoring inspection of Reata. We did not receive any observations.
`We also recently completed a mid-cycle communication meeting with
`the FDA. While we have not yet received formal minutes from the
`FDA, in the preliminary agenda for, and during, the meeting, the FDA
`identified four significant clinical and statistical review issues for us
`to address. The FDA invited us to respond to its identified issues in
`follow-up submissions to the NDA, and we believe each of the
`identified issues is addressable with additional data and analyses. The
`FDA did not designate any safety issues as significant issues, and it
`stated that, based on its current review, it does not believe a Risk
`Evaluation and Mitigation Strategies (“REMS”) program is needed.
`The FDA also advised us that an Advisory Committee meeting is
`tentatively scheduled for December 8, 2021. The Prescription Drug
`
`13
`
`

`

`Case 2:22-cv-00903 Document 1 Filed 02/18/22 Page 14 of 28 PageID: 14
`
`
`
`
`
`User Fee Act (“PDUFA”) date, the FDA action date for the
`application, is scheduled for February 25, 2022.
`
`23. On August 9, 2021, Reata filed its quarterly report on Form 10-Q for
`
`the period ended June 30, 2021, stating, in relevant part:
`
`Bardoxolone in Patients with CKD Caused by Alport Syndrome
`
`On April 26, 2021, we announced that the U.S. Food and Drug
`Administration (FDA) accepted for filing the NDA for bardoxolone
`for the treatment of patients with CKD caused by Alport syndrome,
`and the NDA is currently under review by the FDA. The FDA
`completed a bio-research monitoring inspection of Reata. We did not
`receive any observations. We also recently completed a mid-cycle
`communication meeting with the FDA. While we have not yet
`received formal minutes from the FDA, in the preliminary agenda
`for, and during, the meeting, the FDA identified four significant
`clinical and statistical review issues. We believe each of these issues
`are addressable with additional data and analyses, and the FDA
`invited us to address its identified issues in follow-up submissions to
`the NDA. We plan to address each of the issues through the
`submission of additional data and analyses to the NDA. See Programs
`in Chronic Kidney Disease – Bardoxolone in Patients with CKD
`Caused by Alport Syndrome below.
`
`The FDA made additional information requests and identified a few
`additional issues that were not deemed significant. The FDA did not
`designate any safety issues as significant issues, and it stated that,
`based on its current review, it does not believe a Risk Evaluation and
`Mitigation Strategies (REMS) program is needed. We were notified
`that we would be receiving comments in writing regarding Chemistry,
`Manufacturing, and Controls (CMC), and we will not be receiving any
`nonclinical comments. The FDA also advised us that an Advisory
`Committee meeting is tentatively scheduled for December 8, 2021.
`The Prescription Drug User Fee Act (PDUFA) date, the FDA action
`date for the application, is scheduled for February 25, 2022.
`
`(Emphasis added.)
`
`
`14
`
`

`

`Case 2:22-cv-00903 Document 1 Filed 02/18/22 Page 15 of 28 PageID: 15
`
`
`
`
`
`24. The above statements identified in ¶¶ 15-23 were materially false
`
`and/or misleading, and failed to disclose material adverse facts about the
`
`Company’s business, operations, and prospects. Specifically, Defendants failed to
`
`disclose to investors that: (1) the FDA had raised concerns regarding the validity
`
`of the clinical study designed to measure the efficacy and safety of bardoxolone
`
`for the treatment of CKD caused by AS; (2) as a result, there was a material risk
`
`that Reata’s NDA would not be approved; and (3) as a result of the foregoing,
`
`Defendants’ positive statements about the Company’s business, operations, and
`
`prospects were materially misleading and/or lacked a reasonable basis.
`
`THE TRUTH EMERGES
`
`25. On December 6, 2021, the FDA released briefing documents in
`
`advance of an Advisory Committee meeting for the Company’s NDA for
`
`bardoxolone, stating that the agency had repeatedly questioned the validity of
`
`Reata’s study design because bardoxolone’s pharmacodynamic effect on kidney
`
`function would make the results difficult to assess the effectiveness of the drug.
`
`Specifically, the briefing document noted that, “[i]n September 2018, FDA
`
`encouraged [Reata] to request an end-of-phase 2 meeting to discuss the
`
`development program and ensure alignment,” but Reata declined. Then, in
`
`February 2019, the FDA “emphasized the importance of obtaining FDA
`
`concurrence that a study intended to support a marketing application was adequate
`
`15
`
`

`

`Case 2:22-cv-00903 Document 1 Filed 02/18/22 Page 16 of 28 PageID: 16
`
`
`
`
`
`and acceptable for this purpose.” The briefing document detailed the concerns the
`
`FDA had raised with Reata during the course of the clinical studies and NDA
`
`submission:
`
`• Bardoxolone’s pharmacodynamic effect on eGFR and assessing
`for effects on disease progression: At a preIND meeting held in
`October 2016,
`the Division
`indicated
`that because of
`bardoxolone’s pharmacodynamic effect on kidney function, on-
`treatment assessments of kidney function would be difficult to
`interpret as a drug effect on disease progression. As such, a
`post-treatment assessment of creatinine should be used to assess
`bardoxolone’s efficacy in treating the disease. Following
`submission of the IND in 2016, the Agency repeatedly voiced
`concerns about
`the
`time-course
`for
`resolution of
`bardoxolone’s pharmacodynamic effect on creatinine/eGFR
`following discontinuation of treatment and whether the off-
`treatment values collected in CARDINAL Phase 3 were in fact
`capturing an effect on disease progression. The Agency
`ultimately recommended that the Applicant conduct a separate
`study to characterize the time course for resolution of
`bardoxolone’s pharmacodynamic effect or modify CARDINAL
`Phase 3 to obtain the information (i.e., revise the protocol to
`include additional off-treatment eGFR measurements).
`• Accelerated Approval: In January and September 2020, the
`Applicant met with Agency to discuss submission of an NDA
`for bardoxolone under the accelerated approval pathway based
`primarily on the Year 1 data on eGFR from CARDINAL Phase
`3. The Division did not agree with the proposed approach,
`voicing concerns about the interpretability of the eGFR
`findings given the available information on the time course
`for resolution of bardoxolone’s pharmacodynamic effect, as
`well as the amount of missing data in the bardoxolone arm
`and lack of clarity on how patients with missing data were
`handled in key analyses intended to disentangle the drug’s
`pharmacodynamic effect on kidney function from its effect on
`the irreversible loss of kidney function.
`
`16
`
`

`

`Case 2:22-cv-00903 Document 1 Filed 02/18/22 Page 17 of 28 PageID: 17
`
`• Bardoxolone’s effects on blood pressure and albuminuria: At
`the January and September 2020 meetings with the Applicant,
`the Agency voiced concern about bardoxolone’s effects on
`blood pressure and albuminuria and whether, over the long
`term, these effects could accelerate progression to kidney
`failure.
`• Trial integrity: In November 2020, the Applicant submitted an
`addendum to their SAP dated October 30, 2020, and an
`amended Data Access Plan dated August 28, 2020 for
`CARDINAL Phase 3. In its December 2020 response to the
`submission, the Agency expressed concern about the number of
`individuals with access to patient-level clinical data and
`individual treatment assignments following the interim analysis
`of data from Year 1, as well as the late changes to the study’s
`SAP, and provided specific recommendations on additional
`information and analyses that should be included in the
`Applicant’s marketing application to address the integrity of the
`trial data. [Footnote omitted.]
`
`
`(Emphasis added.)
`
`
`
`
`
`
`
`26. Though the FDA agreed that Reata’s Phase 3 study met its endpoints,
`
`“the FDA review team d[id] not believe the submitted data demonstrate that
`
`bardoxolone is effective in slowing the loss of kidney function in patients with AS
`
`and reducing the risk of progression to kidney failure.” Among other things, the
`
`FDA noted that a “treatment can have both reversible [pharmacodynamic] effects
`
`on kidney function as well as change the trajectory of the decline in kidney
`
`function . . . , but it can be difficult to tease apart the contribution of each
`
`component in trials with short treatment duration and/or when off-treatment
`
`17
`
`

`

`Case 2:22-cv-00903 Document 1 Filed 02/18/22 Page 18 of 28 PageID: 18
`
`
`
`
`
`measurements of eGFR are obtained before the pharmacodynamic effect on eGFR
`
`has fully reversed.” It further stated:
`
`The CARDINAL Phase 3 study consisted of two years of longitudinal
`on-treatment eGFR assessments with two 4-week washout periods,
`after Year 1 and Year 2, respectively. The time-course of eGFR
`changes in the bardoxolone and placebo groups is shown in Figure 4
`[omitted]. eGFR increased compared to placebo while on treatment at
`Week 48 and Week 100, as evaluated by the primary efficacy
`endpoint; however, eGFR decreased during each of the 4-week
`washout periods, suggesting that the on-treatment increase in eGFR
`was, at least in part, a result of the reversible PD effect of bardoxolone
`on eGFR. If the duration of the washout was long enough to eliminate
`the reversible PD effect on eGFR, then changes in eGFR compared
`with placebo at the end of the Year-2 washout period could indicate
`bardoxolone’s effect on slowing disease progression. A key issue was
`to determine if the study’s 4-week washout was long enough for the
`reversible PD effect on eGFR to have resolved.
`
`[Reata] has justified the 4-week washout in CARDINAL Phase 3
`based on: various pooled analyses of patients across studies with
`eGFR measurements collected up to 42 days off-treatment; off-
`treatment eGFR measurements for studies in patients with CKD with
`treatment duration ≤8 weeks; the pharmacokinetic (PK) profile of
`bardoxolone; exposure-response modeling; and time to return to
`baseline of other PD markers, such as liver enzymes. The FDA has
`not found these justifications compelling to support the adequacy of
`a 4-week washout in patients with AS, as d

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket